Publications by authors named "Kenneth J Barr"

Claim this Profile
S
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Justin A Caravella, Jian Lin, R Bruce Diebold, Ann-Marie Campbell, Anna Ericsson, Kenneth J Barr

J Med Chem· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Jian Lin, Wei Lu, Justin A Caravella, Ann Marie Campbell, R Bruce Diebold, Kenneth J Barr

J Med Chem· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.
Min Zhong, Thomas R Gadek, Minna Bui, Wang Shen, John Burnier, Kenneth J Barr

ACS Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.
Min Zhong, Emily J Hanan, Wang Shen, Minna Bui, Michelle R Arkin, Kenneth J Barr

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.
Min Zhong, Wang Shen, Kenneth J Barr, Jennifer P Arbitrario, Michelle R Arkin

Bioorg Med Chem Lett· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo.
Paul S Marinec, Lei Chen, Kenneth J Barr, Mitchell W Mutz, Gerald R Crabtree

Proc Natl Acad Sci U S A· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Raymond V Fucini, Emily J Hanan, Michael J Romanowski, Robert A Elling, Willard Lew, Kenneth J Barr

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme.
Robert A Elling, Raymond V Fucini, Emily J Hanan, Kenneth J Barr, Jiang Zhu

Acta Crystallogr Sect F Struct Biol Cryst Commun· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric inhibition of protein tyrosine phosphatase 1B.
Christian Wiesmann, Kenneth J Barr, Jenny Kung, Jiang Zhu, Daniel A Erlanson

Nat Struct Mol Biol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.
Le Wang, Keith W Woods, Qun Li, Kenneth J Barr, Richard W McCroskey

J Med Chem· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.
Qun Li, Keith W Woods, Akiyo Claiborne, Stephen L Gwaltney, Kenneth J Barr

Bioorg Med Chem Lett· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis